AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of Mitotic checkpoint serine/threonine-protein kinase BUB1 beta including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into Mitotic checkpoint serine/threonine-protein kinase BUB1 beta therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of Mitotic checkpoint serine/threonine-protein kinase BUB1 beta, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on Mitotic checkpoint serine/threonine-protein kinase BUB1 beta. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of Mitotic checkpoint serine/threonine-protein kinase BUB1 beta. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for Mitotic checkpoint serine/threonine-protein kinase BUB1 beta includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Mitotic checkpoint serine/threonine-protein kinase BUB1 beta
partner:
Reaxense
upacc:
O60566
UPID:
BUB1B_HUMAN
Alternative names:
MAD3/BUB1-related protein kinase; Mitotic checkpoint kinase MAD3L; Protein SSK1
Alternative UPACC:
O60566; B2R6U0; B4DL09; B4DLG3; O60501; O60627; O60758; O75389; Q59HH6; Q8WV50; Q96KM4
Background:
Mitotic checkpoint serine/threonine-protein kinase BUB1 beta, also known as MAD3/BUB1-related protein kinase, plays a pivotal role in mitotic checkpoint signaling. It ensures proper chromosome alignment and distribution by delaying anaphase initiation until all chromosomes are correctly attached to the mitotic spindle. Its functions include inhibiting the anaphase-promoting complex and monitoring kinetochore activities, crucial for maintaining genomic stability.
Therapeutic significance:
BUB1 beta's involvement in diseases like Premature Chromatid Separation Trait and Mosaic Variegated Aneuploidy Syndrome 1, due to its critical role in chromosome segregation, highlights its potential as a target for therapeutic intervention. Understanding its mechanisms could lead to novel treatments for these genetic disorders.
